{"id":15881,"date":"2026-07-31T02:29:52","date_gmt":"2026-07-31T00:29:52","guid":{"rendered":"https:\/\/hqsarms.com\/?p=15881"},"modified":"2026-07-31T02:29:53","modified_gmt":"2026-07-31T00:29:53","slug":"slu-pp-332-full-guide","status":"publish","type":"post","link":"https:\/\/hqsarms.com\/sv\/slu-pp-332-full-guide\/","title":{"rendered":"En omfattande guide till SLU-PP-332: Den nya tr\u00e4ningsmimetiken"},"content":{"rendered":"<p class=\"wp-block-paragraph\"><em>This article was last updated on July 31, 2026.<\/em><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">T\u00e4nk dig att f\u00e5 <strong>f\u00f6rdelarna med motion<\/strong>: better endurance, enhanced metabolism, and improved fat-burning, without ever picking up a dumbbell or lacing up your running shoes. SLU-PP-332 attracted significant media attention following a cluster of preclinical publications from Saint Louis University&#8217;s Burris laboratory in 2023. That attention, and the &#8220;exercise in a pill&#8221; framing that accompanied it, have substantially outpaced the scientific evidence. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">M\u00f6te <strong>SLU-PP-332<\/strong>, a novel compound that is said to <strong>mimic the metabolic effects of exercise<\/strong> genom att aktivera energireglerande receptorer i kroppen. \u00c4ven om den h\u00e4r molekylen fortfarande befinner sig i de tidiga stadierna av forskning, f\u00e5r den snabbt uppm\u00e4rksamhet inom omr\u00e5dena \u00e4mnesoms\u00e4ttning, \u00e5ldrande och prestationsf\u00f6rb\u00e4ttring.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In this article, we will unpack the truth about this novel compound and try to distinguish fact from fiction. <\/p>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-alpha-channel-opacity has-background\" style=\"background-color:#ececec;color:#ececec\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Vad \u00e4r SLU-PP-332?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>SLU-PP-332<\/strong>, ibland kallad SLOOP, \u00e4r en syntetisk liten molekyl som utvecklats av forskare vid <strong>Saint Louis universitet (SLU)<\/strong>. Den fungerar som en <strong>\u00d6strogenrelaterad receptor<\/strong> (ERR) agonist.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">ERR-receptorer spelar en avg\u00f6rande roll i mitokondriell biogenes, oxidativ metabolism och den totala energif\u00f6rbrukningen.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Genom att aktivera ERR\u03b1\/\u03b3 p\u00e5verkar det direkt gener som \u00e4r involverade i <strong>energi production, muskelfunktion och fettmetabolism<\/strong>, som alla \u00e4r centrala egenskaper hos en \u201ctr\u00e4ningsliknande\u201d respons.<\/p>\n\n\n\n<figure class=\"wp-block-image size-medium is-resized\"><img decoding=\"async\" width=\"300\" height=\"124\" src=\"https:\/\/hqsarms.com\/wp-content\/uploads\/2025\/05\/SLU-PP-332_structure-300x124.png\" alt=\"SLU-PP-332 molekyl\u00e4r struktur\" class=\"wp-image-15882\" style=\"width:500px\" srcset=\"https:\/\/hqsarms.com\/wp-content\/uploads\/2025\/05\/SLU-PP-332_structure-300x124.png 300w, https:\/\/hqsarms.com\/wp-content\/uploads\/2025\/05\/SLU-PP-332_structure-1024x424.png 1024w, https:\/\/hqsarms.com\/wp-content\/uploads\/2025\/05\/SLU-PP-332_structure-768x318.png 768w, https:\/\/hqsarms.com\/wp-content\/uploads\/2025\/05\/SLU-PP-332_structure-18x7.png 18w, https:\/\/hqsarms.com\/wp-content\/uploads\/2025\/05\/SLU-PP-332_structure-990x410.png 990w, https:\/\/hqsarms.com\/wp-content\/uploads\/2025\/05\/SLU-PP-332_structure-441x183.png 441w, https:\/\/hqsarms.com\/wp-content\/uploads\/2025\/05\/SLU-PP-332_structure-1320x547.png 1320w, https:\/\/hqsarms.com\/wp-content\/uploads\/2025\/05\/SLU-PP-332_structure-600x248.png 600w, https:\/\/hqsarms.com\/wp-content\/uploads\/2025\/05\/SLU-PP-332_structure-150x62.png 150w, https:\/\/hqsarms.com\/wp-content\/uploads\/2025\/05\/SLU-PP-332_structure.png 1338w\" sizes=\"(max-width: 300px) 100vw, 300px\" \/><figcaption class=\"wp-element-caption\">SLU-PP-332 molekyl\u00e4r struktur<\/figcaption><\/figure>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-alpha-channel-opacity has-background\" style=\"background-color:#ececec;color:#ececec\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Hur fungerar SLU-PP-332?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">De \u00f6strogenrelaterade receptorerna (ERR) \u00e4r <strong>f\u00f6r\u00e4ldral\u00f6sa nukle\u00e4ra receptorer<\/strong>vilket inneb\u00e4r att deras naturliga ligander (om det finns n\u00e5gra) inte har identifierats slutgiltigt. Trots sitt namn binder de inte \u00f6strogen. Ist\u00e4llet reglerar de energimetabolismen i v\u00e4vnader som <strong>hj\u00e4rta, skelettmuskulatur och brunt fett<\/strong>; alla organ med h\u00f6g energif\u00f6rbrukning.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">SLU-PP-332 arbetar genom <strong>bindning till ERR\u03b1 och ERR\u03b3<\/strong>, vilket \u00f6kar transkriptionen av gener som \u00e4r involverade i:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mitokondriell biogenes<\/strong><\/li>\n\n\n\n<li><strong>Oxidation av fettsyror<\/strong><\/li>\n\n\n\n<li><strong>Oxidativ fosforylering<\/strong><\/li>\n\n\n\n<li><strong>Upptag och anv\u00e4ndning av glukos<\/strong><\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Med andra ord s\u00e4ger det till din kropp att agera som om den befinner sig i ett tillst\u00e5nd av <strong>regelbunden aerobisk tr\u00e4ning<\/strong>\u00e4ven n\u00e4r du sitter stilla.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-alpha-channel-opacity has-background\" style=\"background-color:#ececec;color:#ececec\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Forskningsresultat<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">I en banbrytande studie fr\u00e5n 2023, ledd av forskare vid SLU, testades effekterna av SLU-PP-332 i <strong>stillasittande m\u00f6ss<\/strong> under flera veckor. H\u00e4r \u00e4r vad de hittade:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>\ud83c\udfc3\u200d\u2642\ufe0f <strong>\u00d6kad uth\u00e5llighet<\/strong>: M\u00f6ss som behandlades med SLU-PP-332 kunde <strong>l\u00f6pa betydligt l\u00e4ngre<\/strong> p\u00e5 ett l\u00f6pband j\u00e4mf\u00f6rt med obehandlade kontroller, trots att de inte genomgick n\u00e5gon fysisk tr\u00e4ning.<\/li>\n\n\n\n<li>\ud83d\udd0b <strong>Mitokondriellt genuttryck<\/strong>: F\u00f6reningen uppreglerade gener associerade med <strong>Energimetabolism<\/strong> i skelettmuskulaturen, vilket efterliknar den transkriptionella signatur som ses hos motionerade djur.<\/li>\n\n\n\n<li>\ud83d\udd25 <strong>Utnyttjande av fett<\/strong>: Det skedde en \u00f6kning av <strong>lipidmetabolism<\/strong>vilket tyder p\u00e5 att m\u00f6ssen f\u00f6rbr\u00e4nde mer fett som br\u00e4nsle.<\/li>\n\n\n\n<li>\ud83e\uddec <strong>Ingen hj\u00e4rthypertrofi<\/strong>: Till skillnad fr\u00e5n vissa andra metaboliska f\u00f6rst\u00e4rkare (som GW501516) verkade SLU-PP-332 inte orsaka negativ remodellering av hj\u00e4rtat, vilket \u00e4r ett positivt tecken f\u00f6r s\u00e4kerheten.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Dessa resultat har f\u00e5tt vissa att beskriva SLU-PP-332 som en <strong>\u201cMolekyl\u00e4r genv\u00e4g till god kondition<\/strong>\u201c, men den frasen kommer med vissa f\u00f6rbeh\u00e5ll, som vi kommer att diskutera nedan.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-alpha-channel-opacity has-background\" style=\"background-color:#ececec;color:#ececec\"\/>\n\n\n\n<h3 class=\"wp-block-heading\">SLU-PP-332 j\u00e4mf\u00f6rt med andra tr\u00e4ningsmimetika<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Det finns idag flera preparat som syftar till att efterlikna eller f\u00f6rst\u00e4rka effekterna av tr\u00e4ning genom farmakologiska medel. Hur st\u00e5r sig SLU-PP-332 i j\u00e4mf\u00f6relse med dessa andra tr\u00e4ningsmimetika?<\/p>\n\n\n\n<figure class=\"wp-block-table is-style-stripes\"><table class=\"has-fixed-layout\"><thead><tr><th class=\"has-text-align-left\" data-align=\"left\">Sammans\u00e4ttning<\/th><th class=\"has-text-align-left\" data-align=\"left\">M\u00e5l<\/th><th class=\"has-text-align-left\" data-align=\"left\">Huvudsaklig effekt<\/th><\/tr><\/thead><tbody><tr><td class=\"has-text-align-left\" data-align=\"left\"><strong>SLU-PP-332<\/strong><\/td><td class=\"has-text-align-left\" data-align=\"left\">ERR\u03b1 \/ ERR\u03b3<\/td><td class=\"has-text-align-left\" data-align=\"left\">Mitokondriell biogenes, uth\u00e5llighet<\/td><\/tr><tr><td class=\"has-text-align-left\" data-align=\"left\"><strong>SR-9009<\/strong><\/td><td class=\"has-text-align-left\" data-align=\"left\">REV-ERB\u03b1<\/td><td class=\"has-text-align-left\" data-align=\"left\">Dygnsrytm, \u00e4mnesoms\u00e4ttning<\/td><\/tr><tr><td class=\"has-text-align-left\" data-align=\"left\"><strong>GW-501516<\/strong><\/td><td class=\"has-text-align-left\" data-align=\"left\">PPAR\u03b4<\/td><td class=\"has-text-align-left\" data-align=\"left\">Fettf\u00f6rbr\u00e4nning, uth\u00e5llighet<\/td><\/tr><tr><td class=\"has-text-align-left\" data-align=\"left\"><strong>GW-0742<\/strong><\/td><td class=\"has-text-align-left\" data-align=\"left\">PPAR\u03b4<\/td><td class=\"has-text-align-left\" data-align=\"left\">Fettf\u00f6rbr\u00e4nning, uth\u00e5llighet<\/td><\/tr><tr><td class=\"has-text-align-left\" data-align=\"left\"><strong>AICAR<\/strong><\/td><td class=\"has-text-align-left\" data-align=\"left\">AMPK<\/td><td class=\"has-text-align-left\" data-align=\"left\">Cellul\u00e4r energisensor<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Det som g\u00f6r SLU-PP-332 s\u00e4rskilt lovande \u00e4r dess <strong>direkt verkan p\u00e5 gener som \u00e4r involverade i energimetabolismen<\/strong>utan de off-target-effekter eller toxicitetsprofiler som har hems\u00f6kt andra mimetika.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-alpha-channel-opacity has-background\" style=\"background-color:#ececec;color:#ececec\"\/>\n\n\n\n<figure class=\"wp-block-image size-large\"><img fetchpriority=\"high\" decoding=\"async\" width=\"1024\" height=\"427\" src=\"https:\/\/hqsarms.com\/wp-content\/uploads\/2026\/01\/SLU-PP-332-benefits-1024x427.jpg\" alt=\"F\u00f6rdelar med SLU-PP-332\" class=\"wp-image-19266\" srcset=\"https:\/\/hqsarms.com\/wp-content\/uploads\/2026\/01\/SLU-PP-332-benefits-1024x427.jpg 1024w, https:\/\/hqsarms.com\/wp-content\/uploads\/2026\/01\/SLU-PP-332-benefits-300x125.jpg 300w, https:\/\/hqsarms.com\/wp-content\/uploads\/2026\/01\/SLU-PP-332-benefits-768x320.jpg 768w, https:\/\/hqsarms.com\/wp-content\/uploads\/2026\/01\/SLU-PP-332-benefits-18x8.jpg 18w, https:\/\/hqsarms.com\/wp-content\/uploads\/2026\/01\/SLU-PP-332-benefits-990x413.jpg 990w, https:\/\/hqsarms.com\/wp-content\/uploads\/2026\/01\/SLU-PP-332-benefits-441x184.jpg 441w, https:\/\/hqsarms.com\/wp-content\/uploads\/2026\/01\/SLU-PP-332-benefits-600x250.jpg 600w, https:\/\/hqsarms.com\/wp-content\/uploads\/2026\/01\/SLU-PP-332-benefits-150x63.jpg 150w, https:\/\/hqsarms.com\/wp-content\/uploads\/2026\/01\/SLU-PP-332-benefits.jpg 1200w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">Potentiella f\u00f6rdelar<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Studier p\u00e5 m\u00e4nniskor beh\u00f6vs f\u00f6r att bekr\u00e4fta till\u00e4mpningar i verkligheten, men <strong>prekliniska data<\/strong> f\u00f6resl\u00e5r att SLU-PP-332 i slut\u00e4ndan kan vara anv\u00e4ndbar f\u00f6r:<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>F\u00f6rb\u00e4ttrad uth\u00e5llighet<\/strong><br>\u00c4ven i avsaknad av tr\u00e4ning \u00f6kar f\u00f6reningen mitokondriell funktion och aerob kapacitet i muskelv\u00e4vnad.<\/li>\n\n\n\n<li><strong>Behandling av metabola st\u00f6rningar<\/strong><br>Sjukdomar som fetma, typ 2-diabetes och fettlever kan gynnas av \u00f6kad mitokondrieaktivitet och f\u00f6rb\u00e4ttrad fettoxidation.<\/li>\n\n\n\n<li><strong>Motverka muskelf\u00f6rtvining<\/strong><br>Vid tillst\u00e5nd som \u00e5ldrande, cancerkakexi eller l\u00e5ngvarigt s\u00e4ngl\u00e4ge kan SLU-PP-332 bidra till att bevara muskelfunktionen och energimetabolismen.<\/li>\n\n\n\n<li><strong>L\u00e5ng livsl\u00e4ngd och anti-aging<\/strong><br>\u00c4ven om det \u00e4r spekulativt, \u00e4r allt som f\u00f6rb\u00e4ttrar mitokondriernas funktion av intresse f\u00f6r m\u00e4nniskor som str\u00e4var efter ett l\u00e5ngt liv. Eftersom mitokondriernas f\u00f6rs\u00e4mring \u00e4r kopplad till \u00e5ldrandet skulle en \u00f6kning av deras prestanda kunna vara ett kraftfullt ingripande.<\/li>\n<\/ol>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-alpha-channel-opacity has-background\" style=\"background-color:#ececec;color:#ececec\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Biverkningar<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Varje substans - s\u00e4rskilt en ny s\u00e5dan - har sina f\u00f6rbeh\u00e5ll. S\u00e5 vilka \u00e4r de potentiella nackdelarna med SLU-PP-332? S\u00e5 h\u00e4r l\u00e5ngt, <strong>djurstudier har inte rapporterat allvarliga biverkningar<\/strong> eller toxicitet vid effektiva doser av SLU-PP-332. M\u00f6ss som behandlades i flera veckor visade f\u00f6rb\u00e4ttringar i olika h\u00e4lsomark\u00f6rer utan uppenbara skador. \u00c4ven om detta \u00e4r uppmuntrande \u00e4r det l\u00e5ngt ifr\u00e5n en garanti f\u00f6r s\u00e4kerhet hos m\u00e4nniskor. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Den mest betydande begr\u00e4nsningen \u00e4r helt enkelt <strong>brist p\u00e5 l\u00e5ngsiktiga data om m\u00e4nniskor<\/strong>. Det \u00e4r oklart hur kronisk aktivering av ERR\u03b1 kan p\u00e5verka olika organ under l\u00e5nga perioder. Till exempel, medan ERR\u03b1-aktivering \u00f6kar \u00e4mnesoms\u00e4ttningen (vilket \u00e4r bra f\u00f6r prestation och fettf\u00f6rbr\u00e4nning), kan ett \u00f6veraktivt metaboliskt tillst\u00e5nd potentiellt stressa vissa v\u00e4vnader eller st\u00f6ra hormonbalansen p\u00e5 s\u00e4tt som vi \u00e4nnu inte f\u00f6rst\u00e5r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Eftersom det finns <strong>inga f\u00f6rs\u00f6k p\u00e5 m\u00e4nniskor med SLU-PP-332<\/strong>m\u00e5ste vi f\u00f6rlita oss p\u00e5 anekdotiska bevis och anv\u00e4ndarrapporter f\u00f6r eventuella biverkningar. Det finns flera inl\u00e4gg p\u00e5 Reddit s\u00e5v\u00e4l som andra k\u00e4llor med anv\u00e4ndarupplevelser, som n\u00e4mner n\u00e5gra av dem:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>En (l\u00e4tt) \u00f6kning av kroppstemperaturen under cirka 30 minuter efter dosering. <\/strong><\/li>\n\n\n\n<li><strong>En viss niv\u00e5 av utmattning efter den initiala \u00f6kningen av energi. <\/strong><\/li>\n\n\n\n<li><strong>\u00d6kad svettning n\u00e4r du tr\u00e4nar. <\/strong><\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Ingen av dessa potentiella biverkningar \u00e4r chockerande och vad man kan f\u00f6rv\u00e4nta sig baserat p\u00e5 den handlingsmetod som \u00e4r f\u00f6rknippad med denna speciella f\u00f6rening.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-alpha-channel-opacity has-background\" style=\"background-color:#ececec;color:#ececec\"\/>\n\n\n\n<h3 class=\"wp-block-heading\">Vem \u00e4r intresserad av SLU-PP-332?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">SLU-PP-332 har trots sitt tidiga skede v\u00e4ckt intresse i flera kretsar:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Akademiska forskare<\/strong> studerar metaboliska sjukdomar, tr\u00e4ningsbiologi och \u00e5ldrande.<\/li>\n\n\n\n<li><strong>Biohackare<\/strong> utforskar nya gr\u00e4nser inom prestation och \u00e5terh\u00e4mtning (om \u00e4n i f\u00f6rtid).<\/li>\n\n\n\n<li><strong>L\u00e4kemedelsutvecklare<\/strong> med tanke p\u00e5 mimetiska tr\u00e4ningsformer som verktyg f\u00f6r behandling av kroniska sjukdomar.<\/li>\n\n\n\n<li><strong>Idrottare och tr\u00e4nare<\/strong>\u00e4ven om anv\u00e4ndningen inom idrotten fortfarande \u00e4r spekulativ och etiskt k\u00e4nslig.<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-alpha-channel-opacity has-background\" style=\"background-color:#ececec;color:#ececec\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Dosering och administrering<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">Forskningsresultat<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Eftersom SLU-PP-332 f\u00f6r n\u00e4rvarande \u00e4r en forskningssubstans finns det ingen standardiserad \"dos\" eller anv\u00e4ndningsprotokoll f\u00f6r m\u00e4nniskor. Att f\u00f6rst\u00e5 hur det har anv\u00e4nts i studier ger dock en viss inblick. I djurf\u00f6rs\u00f6k, <strong>relativt h\u00f6ga doser<\/strong> kr\u00e4vdes f\u00f6r att se de dramatiska effekterna. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">En typisk behandling av m\u00f6ss var cirka <strong>50 mg per kilogram kroppsvikt, givet tv\u00e5 g\u00e5nger dagligen<\/strong> under flera veckor. F\u00f6r en m\u00e4nniska p\u00e5 70 kg skulle en motsvarande skalad dos vara extremt stor (flera gram per dag) - l\u00e5ngt \u00f6ver vad n\u00e5gon i praktiken skulle ta. Det \u00e4r troligt att om SLU-PP-332 n\u00e5gonsin g\u00e5r vidare till f\u00f6rs\u00f6k p\u00e5 m\u00e4nniskor kommer de effektiva doserna att vara mycket mindre, med tanke p\u00e5 skillnader i \u00e4mnesoms\u00e4ttning och f\u00f6reningens h\u00f6ga potens vid sitt m\u00e5l (den aktiverar ERR\u03b1 vid nanomol\u00e4ra koncentrationer)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">N\u00e4r det g\u00e4ller <strong>administration<\/strong>I tidiga studier levererades SLU-PP-332 ofta via injektion. Till exempel rapporterade forskargrupper att de injicerade f\u00f6reningen i m\u00f6ss (intraperitonealt) f\u00f6r att s\u00e4kerst\u00e4lla konsekvent absorption. Utvecklarna har noterat ett behov av att <strong>f\u00f6rfina substansen till en oral tablettform<\/strong>, eftersom ett piller som \u00e4r l\u00e4tt att ta skulle vara att f\u00f6redra f\u00f6r m\u00e4nsklig anv\u00e4ndning. <\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Biotillg\u00e4nglighet <\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">SLU-PP-332 verkar ha en <strong>mycket anst\u00e4ndig oral biotillg\u00e4nglighet (~ 45%)<\/strong> i gnagarmodeller, vilket inneb\u00e4r att n\u00e4stan h\u00e4lften av en oral dos kan n\u00e5 blodomloppet - ett tecken p\u00e5 att oral dosering kan vara livskraftig. I samma studie fastst\u00e4lldes det att f\u00f6reningens halveringstid \u00e4r cirka 8-10 timmar hos gnagare, vilket tyder p\u00e5 att framtida anv\u00e4ndare kan beh\u00f6va en <strong>Doseringsschema tv\u00e5 g\u00e5nger dagligen<\/strong> f\u00f6r att uppr\u00e4tth\u00e5lla stabila niv\u00e5er.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">P\u00e5 grund av avsaknaden av studier p\u00e5 m\u00e4nniskor \u00e4r det os\u00e4kert om biotillg\u00e4ngligheten hos m\u00e4nniskor \u00e4r densamma som hos gnagare. Faktorer s\u00e5som f\u00f6rekomst eller fr\u00e5nvaro av maginneh\u00e5ll kan p\u00e5verka effektiviteten hos denna f\u00f6rening n\u00e4r den tas oralt. Av denna anledning, <strong>Vissa anv\u00e4ndare f\u00f6redrar att ta SLU-PP-332 sublingualt.<\/strong>.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-alpha-channel-opacity has-background\" style=\"background-color:#ececec;color:#ececec\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Preclinical research findings<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">All currently available efficacy data for SLU-PP-332 come from mouse studies. None of the findings listed below have been replicated in humans. Individual results in humans, if any studies were ever conducted, may differ substantially, and all of the following findings describe observations in specific animal models under specific experimental conditions.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Endurance and skeletal muscle gene expression<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The foundational characterization of SLU-PP-332&#8217;s in vivo effects appeared in\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36988910\/\" target=\"_blank\" rel=\"noopener\">the 2023\u00a0<em>ACS Kemisk biologi<\/em>\u00a0paper<\/a>\u00a0by Billon, Sitaula, Banerjee, and colleagues from the Burris laboratory. In this preclinical study, mice (n = 6 per group) received SLU-PP-332 at 50 mg\/kg intraperitoneally, either as a single acute dose 1 hour before treadmill testing or as chronic twice-daily dosing over a 10 day period. The results were compared against vehicle (DMSO) controls.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Treated mice showed increased treadmill running distance and time relative to vehicle controls, alongside induction of an ERR\u03b1-dependent acute aerobic exercise gene program in skeletal muscle (including upregulation of Ddit4 and Slc25a25). This is <strong>consistent with observations after endurance exercise<\/strong>. The activated gene program included targets associated with fatty acid oxidation, components of the mitochondrial electron transport chain, and oxidative fiber specification. <\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Metabolic syndrome and body composition<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">A\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37739806\/\" target=\"_blank\" rel=\"noopener\">2024 follow-up paper<\/a>\u00a0by Billon, Schoepke, Avdagic, and colleagues published in the\u00a0<em>Journal of Pharmacology and Experimental Therapeutics<\/em>\u00a0examined SLU-PP-332 across three mouse models: C57Bl6 mice on normal chow (n = 8 per group), diet-induced obese mice on high-fat diet (n = 7 per group), and leptin-deficient ob\/ob mice (n = 8 per group), with treatment durations of 15 to 28 days depending on model.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In comparison to vehicle controls, DIO mice treated with SLU-PP-332 showed less fat mass accumulation and a reduction in adipocyte size. Over 15 days, ob\/ob mice also showed a decrease in fat mass. Additionally, the treated animals e<strong>xhibited increased energy expenditure<\/strong>, <strong>enhanced fatty acid oxidation<\/strong>och <strong>improved insulin sensitivity in metabolic syndrome models<\/strong>, with key comparisons yielding p-values ranging from &lt;0.05 to &lt;0.0001, as noted in the published figures. However, no improvement in glucose metabolism was observed in mice fed a normal chow diet. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">These findings support claims regarding the potential relevance of SLU-PP-332 to fat oxidation and weight-related outcomes.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Cardiac function in heart failure models<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">A\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37961903\/\" target=\"_blank\" rel=\"noopener\">2024 paper<\/a>\u00a0by Xu, Billon, Li, and colleagues published in\u00a0<em>Circulation<\/em>\u00a0examined pan-ERR agonists (including SLU-PP-332 and its successor compound SLU-PP-915) in the mouse transverse aortic constriction model of pressure-overload heart failure. In 8-week-old mice following 27-gauge TAC surgery, the administration of SLU-PP-332 at a dosage of 25 mg\/kg intraperitoneally twice daily for a treatment period of up to 6 weeks (with sample sizes ranging from 4 to 23 per measurement) resulted in significant improvements in ejection fraction and a reduction in cardiac fibrosis (p &lt; 0.05 compared to sham-vehicle). Additionally, the treatment increased survival rates and enhanced cardiac fatty acid metabolism and mitochondrial oxidative capacity when compared to vehicle-treated TAC controls. However, it did not affect cardiac hypertrophy.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This study extends the preclinical rationale for ERR agonism beyond skeletal muscle into the field of cardiac biology. It also highlights the necessity for a cardiac safety evaluation of this compound as a priority in any future clinical development, a step that has not yet been initiated for SLU-PP-332.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-alpha-channel-opacity has-background\" style=\"background-color:#ececec;color:#ececec\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Anekdotiska bevis och anv\u00e4ndarrapporter <\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Som vi n\u00e4mnde tidigare har inga kliniska pr\u00f6vningar p\u00e5 m\u00e4nniskor \u00e4nnu genomf\u00f6rts p\u00e5 SLU-PP-332. Detta har inte hindrat anv\u00e4ndare inom fitness-, bodybuilding- och biohacking-samh\u00e4llen fr\u00e5n att unders\u00f6ka denna anm\u00e4rkningsv\u00e4rda f\u00f6rening f\u00f6r prestationsh\u00f6jande \u00e4ndam\u00e5l. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">M\u00e5nga anv\u00e4ndarrapporter om SLU-PP-332 finns tillg\u00e4ngliga p\u00e5 Reddit, YouTube och olika andra plattformar. Dessa anekdotiska rapporter ger insikter om doseringar som anv\u00e4nds i sj\u00e4lvexperiment.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Rapporterade doseringsrutiner<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Anv\u00e4ndare rapporterar ett brett spektrum av doser, ofta m\u00e4tt i mikrogram (mcg):<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>L\u00e5ga doser (250\u2013500 mcg\/dag):<\/strong> Vissa personer b\u00f6rjar med 250 mcg p\u00e5 morgonen och ytterligare 250 mcg f\u00f6re eftermiddagens tr\u00e4ning. Denna behandling \u00e4r k\u00e4nd f\u00f6r att \u00f6ka uth\u00e5lligheten och energiniv\u00e5erna utan betydande biverkningar.<\/li>\n\n\n\n<li><strong>M\u00e5ttliga doser (500-1.000 mikrogram\/dag):<\/strong> Andra \u00f6kar till 500 mcg tv\u00e5 g\u00e5nger dagligen och observerar konsekvent fettf\u00f6rlust och f\u00f6rh\u00f6jd kroppstemperatur. Vissa rapporterar dock s\u00f6mnst\u00f6rningar p\u00e5 dessa niv\u00e5er. <\/li>\n\n\n\n<li><strong>H\u00f6ga doser (1.000-2.000 mcg\/dag):<\/strong> En undergrupp av anv\u00e4ndare experimenterar med doser upp till 2,000 mcg dagligen, ofta uppdelade mellan morgon och kv\u00e4ll. Dessa individer rapporterar ofta uttalade effekter p\u00e5 fettmetabolism och energi men varnar ocks\u00e5 f\u00f6r potentiell \u00f6verstimulering.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Rapporterade f\u00f6rm\u00e5ner<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Anekdotiska erfarenheter tyder p\u00e5 flera potentiella f\u00f6rdelar:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>\u00d6kad energi:<\/strong> F\u00f6rh\u00f6jda energiniv\u00e5er och minskad upplevd anstr\u00e4ngning under tr\u00e4ningspassen \u00e4r vanliga exempel.<\/li>\n\n\n\n<li><strong>F\u00f6rb\u00e4ttrad uth\u00e5llighet:<\/strong> Anv\u00e4ndarna noterar f\u00f6rb\u00e4ttrad uth\u00e5llighet under kardiovaskul\u00e4ra tr\u00e4ningspass och styrketr\u00e4ning.<\/li>\n\n\n\n<li><strong>Fettf\u00f6rbr\u00e4nning:<\/strong> Vissa rapporterar accelererad fettminskning, s\u00e4rskilt i kombination med kalorikontrollerade dieter.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Rapporterade biverkningar<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Baserat p\u00e5 samma anv\u00e4ndarrapporter finns det ett par biverkningar rapporterade:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>\u00d6kad svettning<\/strong><\/li>\n\n\n\n<li><strong>S\u00f6mnl\u00f6shet<\/strong> (s\u00e4rskilt vid h\u00f6gre doser)<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-alpha-channel-opacity has-background\" style=\"background-color:#ececec;color:#ececec\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">R\u00e4ttslig status f\u00f6r SLU-PP-332<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Currently, in August 2026, SLU-PP-332 is still in the very early stages of research. As such, it has no FDA or EMA approval, no IND application, and no registered clinical trials in humans. It is not available by prescription, through compounding pharmacies, or through any legitimate therapeutic channel. It is classified as a research tool compound, available only to licensed research institutions for use in preclinical studies.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Eftersom den saknar godk\u00e4nnande fr\u00e5n tillsynsmyndigheter som FDA och EMA kan den inte lagligen s\u00e4ljas som ett kosttillskott och inte heller f\u00f6rskrivas via traditionella medicinska kanaler.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Vid tidpunkten f\u00f6r skrivandet \u00e4r SLU-PP-332 <strong>\u00e4nnu inte listad som ett f\u00f6rbjudet \u00e4mne<\/strong> by WADA or any related institute. Because it targets fat metabolism, it could eventually fall under WADA\u2019s prohibited substance list when its performance-enhancing effects are officially confirmed.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-alpha-channel-opacity has-background\" style=\"background-color:#ececec;color:#ececec\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Var kan jag k\u00f6pa SLU-PP-332 online?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Att hitta en p\u00e5litlig k\u00e4lla \u00e4r avg\u00f6rande om du vill <a href=\"https:\/\/hqsarms.com\/sv\/product\/slu-pp-332-liquid\/\" data-type=\"product\" data-id=\"15459\">k\u00f6p SLU-PP-332<\/a> i Sverige. Genom att v\u00e4lja <strong>en leverant\u00f6r med dokumenterad erfarenhet<\/strong> kvalitet, leverans och support kan du undvika on\u00f6diga risker. HQSARMS har varit en <strong>P\u00e5litlig leverant\u00f6r av liquid, SARM och relaterade forskningskemikalier sedan 2019.<\/strong>, och betj\u00e4nar tusentals kunder \u00f6ver hela Europa. <\/p>\n\n\n\n<figure class=\"wp-block-image size-medium\"><a href=\"https:\/\/hqsarms.com\/sv\/product\/slu-pp-332-liquid\/\"><img decoding=\"async\" width=\"300\" height=\"300\" src=\"https:\/\/hqsarms.com\/wp-content\/uploads\/2025\/03\/slu-pp-332-bottle-small-300x300.png\" alt=\"SLU-PP-332 | K\u00f6p SLU-PP-332 liquid 1000mcg\/ml 30ml | HQSARMS\" class=\"wp-image-15460\" srcset=\"https:\/\/hqsarms.com\/wp-content\/uploads\/2025\/03\/slu-pp-332-bottle-small-300x300.png 300w, https:\/\/hqsarms.com\/wp-content\/uploads\/2025\/03\/slu-pp-332-bottle-small-150x150.png 150w, https:\/\/hqsarms.com\/wp-content\/uploads\/2025\/03\/slu-pp-332-bottle-small-12x12.png 12w, https:\/\/hqsarms.com\/wp-content\/uploads\/2025\/03\/slu-pp-332-bottle-small-441x441.png 441w, https:\/\/hqsarms.com\/wp-content\/uploads\/2025\/03\/slu-pp-332-bottle-small-100x100.png 100w, https:\/\/hqsarms.com\/wp-content\/uploads\/2025\/03\/slu-pp-332-bottle-small-600x600.png 600w, https:\/\/hqsarms.com\/wp-content\/uploads\/2025\/03\/slu-pp-332-bottle-small.png 750w\" sizes=\"(max-width: 300px) 100vw, 300px\" \/><\/a><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Att k\u00f6pa SLU-PP-332 fr\u00e5n HQSARMS har flera f\u00f6rdelar:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Kvalitetss\u00e4kring:<\/strong> V\u00e5ra product har en renhet p\u00e5 minst 98% och en doseringsvariation mellan batcher p\u00e5 mindre \u00e4n 5%. <\/li>\n\n\n\n<li><strong>Garanterad leverans:<\/strong> S\u00e5 l\u00e4nge du anger en giltig leveransadress garanterar vi att ditt paket levereras eller att du f\u00e5r full \u00e5terbetalning.  <\/li>\n\n\n\n<li><strong>H\u00f6g dos: <\/strong>HQSARMS SLU-PP-332 liquid doseras med 1000 mcg (eller 1 mg) per ml, medan de flesta leverant\u00f6rer s\u00e4ljer det med 250 mcg\/ml. <\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-alpha-channel-opacity has-background\" style=\"background-color:#ececec;color:#ececec\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Vanliga fr\u00e5gor och svar<a href=\"https:\/\/en.wikipedia.org\/wiki\/SLU-PP-332#:~:text=,6\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a><\/h2>\n\n\n<div id=\"rank-math-faq\" class=\"rank-math-block\">\n<div class=\"rank-math-list\">\n<div id=\"faq-question-1747783419310\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question\">Vilken \u00e4r den orala biotillg\u00e4ngligheten f\u00f6r SLU-PP-332?<\/h3>\n<div class=\"rank-math-answer\">\n\n<p>Forskning i gnagarmodeller har visat att biotillg\u00e4ngligheten f\u00f6r SLU-PP-332 \u00e4r cirka 45%.<\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1747783608789\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question\">P\u00e5verkas \u00f6strogenniv\u00e5erna av SLU-PP-332?<\/h3>\n<div class=\"rank-math-answer\">\n\n<p>Nej, det faktum att denna f\u00f6rening \u00e4r en <strong>agonist f\u00f6r \u00f6strogenrelaterade receptorer<\/strong> (ERR\u03b1 \/ ERR\u03b3) betyder inte att det har n\u00e5gon inverkan p\u00e5 \u00f6strogenniv\u00e5erna. <\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1747783836562\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question\">\u00c4r SLU-PP-332 lagligt?<\/h3>\n<div class=\"rank-math-answer\">\n\n<p>Liksom de flesta andra forskningskemikalier har den inte godk\u00e4nts f\u00f6r m\u00e4nsklig konsumtion av FDA eller n\u00e5gon annan tillsynsmyndighet. Detta inneb\u00e4r i princip att <strong>det \u00e4r endast lagligt n\u00e4r det s\u00e4ljs f\u00f6r forsknings\u00e4ndam\u00e5l<\/strong>. <\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1757882864246\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question\">\u00c4r SLU-PP-332 en peptid?<\/h3>\n<div class=\"rank-math-answer\">\n\n<p>Nej, det g\u00f6r jag inte, <strong>SLU-PP-332 \u00e4r faktiskt inte en peptid<\/strong>utan en sm\u00e5molekyl\u00e4r ERR-agonist (\u00f6strogenrelaterad receptor). Peptider \u00e4r kedjor av aminosyror som \u00e4r sammanl\u00e4nkade med peptidbindningar, och SLU har inte den strukturen.<\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1762116553082\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question\">Vilken SLU-PP-332-dos per dag \u00e4r standard?<\/h3>\n<div class=\"rank-math-answer\">\n\n<p>Baserat p\u00e5 anekdotiska bevis och anv\u00e4ndarrapporter \u00e4r den vanligaste dosen av SLU-PP-332 mellan 250 mcg och 1000 mcg per dag. Det finns ingen faktisk standarddos f\u00f6r detta \u00e4mne, eftersom det \u00e4nnu inte har testats p\u00e5 m\u00e4nniskor. <\/p>\n\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n<hr class=\"wp-block-separator has-text-color has-alpha-channel-opacity has-background\" style=\"background-color:#ececec;color:#ececec\"\/>\n\n\n\n<h3 class=\"wp-block-heading\">Referenser<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Billon, C., et al (2023).<\/strong> \u201c<a href=\"https:\/\/collections.uhsp.edu\/pharm-admin-sciences_pubs\/44\/\" target=\"_blank\" data-schema-attribute=\"about mentions\" rel=\"noreferrer noopener\">En syntetisk ERR-agonist lindrar metabolt syndrom.<\/a>\u201d <em>Journal of Pharmacology and Experimental Therapeutics.<\/em><\/li>\n\n\n\n<li><strong>Billon, C., et al (2022).<\/strong> \u201c<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36988910\/\" target=\"_blank\" data-schema-attribute=\"about mentions\" rel=\"noreferrer noopener\">Syntetisk ERR\u03b1\/\u03b2\/\u03b3-agonist inducerar ett ERR\u03b1-beroende akut aerobiskt tr\u00e4ningsprogram.<\/a>\u201d <em>ACS Chemical Biology.<\/em><\/li>\n\n\n\n<li><strong>Nasri, H. (2024).<\/strong> \u201c<a href=\"https:\/\/www.jrenendo.com\/PDF\/jre-10-e25143.pdf\" target=\"_blank\" data-schema-attribute=\"about mentions\" rel=\"noreferrer noopener\">Nytt hopp om \"SLU-PP-332\" som ett effektivt medel f\u00f6r viktminskning med indirekt njurskyddande effekt; en nefrologisk synvinkel.<\/a>\u201d <em>Journal of Renal Endocrinology.<\/em><\/li>\n\n\n\n<li><strong>Elgendy, B., et al (2024).<\/strong> \u201c<a href=\"https:\/\/fortune.com\/well\/2024\/03\/18\/exercise-mimicking-pill\/\" target=\"_blank\" data-schema-attribute=\"about mentions\" rel=\"noreferrer noopener\">Ett tr\u00e4ningspiller kan snart erbjuda samma f\u00f6rdelar som ett tr\u00e4ningspass.<\/a>\u201d <em>Fortune Well.<\/em><\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>","protected":false},"excerpt":{"rendered":"<p>This article was last updated on July 31, 2026. Imagine getting the benefits of exercise: better endurance, enhanced metabolism, and improved fat-burning, without ever picking up a dumbbell or lacing up your running shoes. SLU-PP-332 attracted significant media attention following a cluster of preclinical publications from Saint Louis University&#8217;s Burris laboratory in 2023. That attention, [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":15892,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_eb_attr":"","iawp_total_views":7380,"footnotes":""},"categories":[17],"tags":[],"class_list":["post-15881","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sarms"],"_links":{"self":[{"href":"https:\/\/hqsarms.com\/sv\/wp-json\/wp\/v2\/posts\/15881","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/hqsarms.com\/sv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/hqsarms.com\/sv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/hqsarms.com\/sv\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/hqsarms.com\/sv\/wp-json\/wp\/v2\/comments?post=15881"}],"version-history":[{"count":2,"href":"https:\/\/hqsarms.com\/sv\/wp-json\/wp\/v2\/posts\/15881\/revisions"}],"predecessor-version":[{"id":22497,"href":"https:\/\/hqsarms.com\/sv\/wp-json\/wp\/v2\/posts\/15881\/revisions\/22497"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/hqsarms.com\/sv\/wp-json\/wp\/v2\/media\/15892"}],"wp:attachment":[{"href":"https:\/\/hqsarms.com\/sv\/wp-json\/wp\/v2\/media?parent=15881"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/hqsarms.com\/sv\/wp-json\/wp\/v2\/categories?post=15881"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/hqsarms.com\/sv\/wp-json\/wp\/v2\/tags?post=15881"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}